Updated:
Regentis Biomaterials Ltd.
We Innovate cartilage repair for better movement. | Regentis is a regenerative medicine company dedicated to developing innovative tissue repair solutions...
Regentis Biomaterials Ltd.
We Innovate cartilage repair for better movement. | Regentis is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on knee injuries and other orthopedic treatments, Regentis’ Gelrin™ platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC® is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate durable and healthy cartilage in a controlled and synchronous process with sustained results.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What is Regentis Biomaterials' primary product candidate?
The company's lead product is GelrinC, a photopolymerized biodegradable hydrogel designed for the repair of articular cartilage defects. It has undergone clinical evaluation for safety and efficacy in treating focal cartilage lesions (per clinical trial registries).
In which regions has Regentis Biomaterials conducted clinical trials?
Clinical activities for GelrinC have been centered in Europe and Israel, based on publicly available clinical trial records. No U.S. FDA trial registration has been identified as of the last update.
Is Regentis Biomaterials a public or private company?
Regentis Biomaterials is a private company. It does not appear listed on any public stock exchange, and its ownership structure is not disclosed.
What is the regulatory status of GelrinC?
GelrinC has been in clinical development but has not received marketing approval from the FDA or European Medicines Agency. The company's regulatory progress beyond reported trials is unconfirmed.
Does Regentis Biomaterials have any disclosed investors or funding rounds?
No verifiable funding rounds or institutional investors are publicly associated with Regentis Biomaterials. The company's capital history is not documented in available sources.
Is Regentis Biomaterials involved in any partnerships or collaborations?
No partnerships or collaborative agreements have been disclosed by the company in public records.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: